Application of preoperative serum CYFRA 21-1 level in the prognosis of colorectal cancer.
10.3760/cma.j.cn112150-20230611-00457
- VernacularTitle:术前血清CYFRA 21-1水平在结直肠癌预后中的应用研究
- Author:
Wen Qi HU
1
;
Hui CONG
2
;
Rong Hua FANG
1
;
Wen Tao YUAN
1
;
Chun Yan MAO
1
;
Jie Rong WANG
2
;
Ying WANG
3
;
Xiu Ying SHI
2
Author Information
1. Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong 226001, China Medical School, Nantong University, Nantong 226001, China.
2. Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong 226001, China.
3. Department of Laboratory Medicine, School of Public Health, Nantong University, Nantong 226019, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Colorectal Neoplasms/pathology*;
CA-19-9 Antigen;
Retrospective Studies;
Neoplasm Staging;
Neoplasm Recurrence, Local/pathology*;
Biomarkers, Tumor
- From:
Chinese Journal of Preventive Medicine
2023;57(10):1613-1619
- CountryChina
- Language:Chinese
-
Abstract:
To explore the predictive value of preoperative serum CYFRA 21-1 in colorectal cancer (CRC) resection patients. In this retrospective study, 456 patients with CRC who received surgical treatment in the Department of General Surgery, Affiliated Hospital of Nantong University from January 2016 to February 2018 were analyzed. Preoperative CYFRA 21-1, CEA, CA19-9 and pathological data of the study subjects were collected. Determine the cut-off value of CYFRA 21-1 based on the X-tile. Chi-square test or Fisher exact probability test were used to compare clinicopathological features in different CYFRA 21-1 level groups. Univariate and multivariate regression analysis of factors affecting 5-year overall survival (OS) and disease-free survival (DFS). Kaplan-Meier survival curves were used to analyze 5-year differences in OS and DFS in CRC patients with different levels of CYFRA 21-1, CEA and CA19-9. Receiver operating characteristic(ROC) was adopted. ROC curves were used to analyze the prognostic efficacy of CYFRA21-1 for CRC, and nomogram maps were used to predict 1, 3, and 5-year survival rates. The results showed that the optimal cut-off values of serum CYFRA 21-1, CEA and CA19-9 were 4.9 ng/ml, 29.2 ng/ml and 72.8 U/ml, respectively. Different gender, tumor size, location, degree of differentiation, depth of invasion, lymph node metastasis and tumor node metastasis (TNM) classification stage were significantly different between the two groups with high and low CYFRA 21-1, the P-values were 0.018,<0.001,<0.001,<0.001, 0.002, 0.001, 0.003, respectively. CYFRA 21-1 (≥4.9 ng/ml) was an independent risk factor for 5-year OS (HR: 4.008, 95%CI: 2.309-6.958, P<0.001) and DFS (HR: 3.75, 95%CI: 2.227-6.314, P<0.001) in CRC patients. CYFRA 21-1 predicts a 5-year AUC of 0.725 and 0.720 for OS and DFS, respectively, and 0.804 and 0.827 for the combination of CEA and CA19-9. Based on the results of multivariate Cox regression analysis, nomogram graphs of OS and DFS were established, the C-indexes were 0.799 and 0.803, respectively. In conclusion, preoperative serum CYFRA 21-1 level may be an independent risk factor affecting the prognosis of patients with colorectal cancer. The prognostic model established by CYFRA 21-1 combined with CEA, CA19-9 and TNM stages may provide references for the prevention of CRC recurrence and clinical decision-making.
